Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
1(13%)
Results Posted
33%(2 trials)
Terminated
1(13%)

Phase Distribution

Ph not_applicable
1
13%
Ph early_phase_1
1
13%
Ph phase_3
2
25%
Ph phase_4
2
25%
Ph phase_1
1
13%

Phase Distribution

2

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
1(14.3%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
2(28.6%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (14.3%)
Phase 11 (14.3%)
Phase 32 (28.6%)
Phase 42 (28.6%)
N/A1 (14.3%)

Trials by Status

terminated113%
recruiting113%
completed675%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_4

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

NCT04373564
completedphase_3

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

NCT05915728
completedphase_3

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

NCT05915702
completed

Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis

NCT03396822
completedearly_phase_1

Novel Imaging Markers in SPMS

NCT05357833
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04373564Phase 4

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting
NCT05915728Phase 3

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

Completed
NCT05915702Phase 3

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

Completed
NCT03396822

Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis

Completed
NCT05357833Early Phase 1

Novel Imaging Markers in SPMS

Completed
NCT04608812Phase 1

Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection

Terminated
NCT02359097Not Applicable

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

Completed
NCT01613417Phase 4

Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8